Vaccination with a Plasmodium chabaudi adami multivalent DNA vaccine cross-protects A/J mice against challenge with P. c. adami DK and virulent Plasmodium chabaudi chabaudi AS parasites

International Journal for Parasitology

Volumn 38, Issue 7, 2008, Pages 819-827

  Scorza, T ^a,b   Grubb, K ^c   Cambos, M ^a   Santamaria, C ^c   Malu, D Tshikudi ^a   Spithill, T W ^b,c,d  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b Gouvernement du Quebec   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Cellular immune responses; Cross protection; DNA vaccines; Genetic restriction; Malaria; Multivalency; Opsonizing antibodies; Plasmodium chabaudi

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; MALARIA VACCINE; MEMBRANE ANTIGEN; PARASITE ANTIGEN;

ANTIBODY; ANTIGEN; DNA; HISTOLOGY; IMMUNE RESPONSE; MALARIA; PARASITE; PROTIST; RESEARCH WORK; RODENT; SURVIVAL; VACCINATION; VIRULENCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; DISEASE MODEL; ERYTHROCYTE; HAPLOTYPE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALARIA; MOUSE; MOUSE STRAIN; NONHUMAN; OPSONIZATION; PARASITE VIRULENCE; PARASITEMIA; PLASMODIUM CHABAUDI; PROTECTION; SPLEEN CELL; SURVIVAL; VACCINATION;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, PROTOZOAN; FEMALE; INTERFERON-GAMMA; MALARIA; MICE; MICE, INBRED A; OPSONIN PROTEINS; PARASITEMIA; PLASMODIUM CHABAUDI; VACCINATION; VACCINES, DNA; VIRULENCE;

MUS; PLASMODIUM CHABAUDI; PLASMODIUM CHABAUDI ADAMI; PLASMODIUM CHABAUDI CHABAUDI;

EID: 41949088383     PISSN: 00207519     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpara.2007.10.009     Document Type: Article

References (60)

1. Anders R.F., Crewther P.E., Edwards S., Margetts M., Matthew M.L., Pollock B., and Pye D. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16 (1998) 240-247
2. Ballou W.P., Arevalo-Herrera M., Carucci D., Richie T.L., Corradin G., Diggs C., Druilhe P., Giersing B.K., Saul A., Heppner D.G., Kester K.E., Lanar D.E., Lyon J., Hill A.V., Pan W., and Cohen J.D. Update on the clinical development of candidate malaria vaccines. Am. J. Trop. Med. Hyg. 71 (2004) 239-247
3. Bouharoun-Tayoun H., Oeuvray C., Lunel F., and Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J. Exp. Med. 182 (1995) 409-418
4. Brahimi K., Badel E., Sauzet J.P., BenMohamed L., Daubersies P., Guerin-Marchand C., Snounou G., and Druilhe P. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infect. Immun. 69 (2001) 3845-3852
5. Bull P.C., and Marsh K. The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol. 10 (2002) 55-58
6. Caroline E.C., and Langhorne J. Plasmodium chabaudi chabaudi (AS): inflammatory cytokines and pathology in an erythrocytic-stage infection in mice. Exp. Parasitol. 90 (1998) 320-329
7. Chatterjee S., Singh S., Sohoni R., Singh N.J., Vaidya A., Long C., and Sharma S. Antibodies against ribosomal phosphoprotein P0 of Plasmodium falciparum protect mice against challenge with Plasmodium yoelii. Infect. Immun. 68 (2000) 4312-4318
8. Chauhan V.S., Chatterjee S., and Johar P.K. Synthetic peptides based on conserved Plasmodium falciparum antigens are immunogenic and protective against Plasmodium yoelii malaria. Parasite Immunol. 15 (1993) 239-242
9. Cortes A., Mellombo M., Mueller I., Benet A., Reeder J.C., and Anders R.F. Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1. Infect. Immun. 71 (2003) 1416-1426
10. Cravo P., Culleton R., Hunt P., Walliker D., and Mackinnon M.J. Antimalarial drugs clear resistant parasites from partially immune hosts. Antimicrob. Agents Chemother. 45 (2001) 2897-2901
11. Crewther P.E., Matthew M.L., Flegg R.H., and Anders R.F. Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes. Infect. Immun. 164 (1996) 3310-3317
12. Doolan D.L., Sedegah M., Hedstrom R.C., Hobart P., Charoenvit Y., and Hoffman S.L. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J. Exp. Med. 183 (1996) 1739-1746
13. Doolan D.L., and Hoffman S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165 (2000) 1453-1462
14. Doolan D.L., and Hoffman S.L. DNA-based vaccines against malaria: status and promise of the Multi-Stage malaria DNA vaccine operation. Int. J. Parasitol. 31 (2001) 753-762
15. Doolan D.L., Aguiar J.C., Weiss W.R., Sette A., Felgner P.L., Regis D.P., Quinones-Casas P., Yates III J.R., Blair P.L., Richie T.L., Hoffman S.L., and Carucci D.J. Utilization of genomic sequence information to develop malaria vaccines. Exp. Biol. 206 (2003) 3789-3802
16. Dunachie S.J., and Hill A.V. Prime-boost strategies for malaria vaccine development. J. Exp. Biol. 206 (2003) 3771-3779
17. Elliot S.R., Kuns R.D., and Good M.F. Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria. Infect. Immun. 73 (2005) 2478-2485
18. Fandeur T., and Chalvet W. Variant- and strain-specific immunity in Saimiri infected with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 58 (1998) 225-231
19. Gardner M.J., Hall N., Fung E., White O., Berriman M., Hyman R.W., Carlton J.M., Pain A., Nelson K.E., Bowman S., Paulsen I.T., James K., Eisen J.A., Rutherford K., Salzberg S.L., Craig A., Kyes S., Chan M.S., Nene V., Shallom S.J., Suh B., Peterson J., Angiuoli S., Pertea M., Allen J., Selengut J., Haft D., Mather M.W., Vaidya A.B., Martin D.M., Fairlamb A.H., Fraunholz M.J., Roos D.S., Ralph S.A., McFadden G.I., Cummings L.M., Subramanian G.M., Mungall C., Venter J.C., Carucci D.J., Hoffman S.L., Newbold C., Davis R.W., Fraser C.M., and Barrell B. Sequence of Plasmodium falciparum chromosomes 2, 10, 11 and 14. Nature 419 (2002) 498-511
20. Genton B., Betuela I., Felger I., Al-Yaman F., Anders R.F., Saul A., Rare L., Baisor M., Lorry K., Brown G.V., Pye D., Irving D.O., Smith T.A., Beck H.P., and Alpers M.P. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J. Infect. Dis. 185 (2002) 820-827
21. Goschnick M.W., Black C.G., Kedzierski L., Holder A.A., and Coppel R.L. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect. Immun. 72 (2004) 5840-5849
22. Haddad D., Bilcikova E., Witney A.A., Carlton J.M., White C.E., Blair P.L., Chattopadhyay R., Russell J., Abot E., Charoenvit Y., Aguiar J.C., Carucci D.J., and Weiss W.R. Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome. Infect. Immun. 72 (2004) 1594-1602
23. Hanke T., Schneider J., Gilbert S.C., Hill A.V., and McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16 (1998) 426-435
24. Healer J., Triglia T., Hodder A.N., Gemmill A.W., and Cowman A.F. Functional analysis of Plasmodium falciparum apical membrane antigen 1 utilizing interspecies domains. Infect. Immun. 73 (2005) 2444-2451
25. Jeffery G.M. Epidemiological significance of repeated infections with homologous and heterologous strains and species of Plasmodium. Bull. World Health Organ. 35 (1966) 873-882
26. Jones T.R., Gramzinski R.A., Aguiar J.C., Sim B.K., Narum D.L., Fuhrmann S.R., Kumar S., Obaldia N., and Hoffman S.L. Absence of antigenic competition in Aotus monkeys immunized with Plasmodium falciparum DNA vaccines delivered as a mixture. Vaccine 20 (2002) 1675-1680
27. Kang Y., Calvo P.A., Daly T.M., and Long C.A. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J. Immunol. 161 (1998) 4211-4219
28. Kraemer S.M., and Smith J.D. A family affair: var genes, PfEMP1 binding, and malaria disease. Curr. Opin. Microbiol. 9 (2006) 374-380
29. Langhorne J., Quin S.J., and Sanni L.A. Mouse models of blood-stage malaria infections: immune responses and cytokines involved in protection and pathology. Chem. Immunol. 80 (2002) 204-228
30. Lord R., Jones G.L., Spencer L., and Saul A. Mice immunized with a synthetic peptide construct corresponding to an epitope present on a Plasmodium falciparum antigen are protected against Plasmodium chabaudi challenge. Parasite Immunol. 15 (1993) 613-618
31. Lougovskoi A.A., Okoyeh N.J., and Chauhan V.S. Mice immunised with synthetic peptide from N-terminal conserved region of merozoite surface antigen-2 of human malaria parasite Plasmodium falciparum can control infection induced by Plasmodium yoelii yoelii 265BY strain. Vaccine 18 (1999) 920-930
32. Mahanty S., Saul A., and Miller L.H. Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J. Exp. Biol. 206 (2003) 3781-3788
33. Makobongo M.O., Riding G., Xu H., Hirunpetcharat C., Keough D., de Jersey J., Willadsen P., and Good M.F. The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc. Natl. Acad. Sci. USA 100 (2003) 2628-2633
34. McConkey S.J., Reece W.H., Moorthy V.S., Webster D., Dunachie S., Butcher G., Vuola J.M., Blanchard T.J., Gothard P., Watkins K., Hannan C.M., Everaere S., Brown K., Kester K.E., Cummings J., Williams J., Heppner D.G., Pathan A., Flanagan K., Arulanantham N., Roberts M.T., Roy M., Smith G.L., Schneider J., Peto T., Sinden R.E., Gilbert S.C., and Hill A.V. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9 (2003) 729-735
35. Moorthy V.S., Good M.F., and Hill A.V.S. Malaria vaccine developments. The Lancet 363 (2004) 150-156
36. Mota M.M., Brown K.N., Holder A.A., and Jarra W. Acute Plasmodium chabaudi chabaudi malaria infection induces antibodies which bind to the surfaces of parasitized erythrocytes and promote their phagocytosis by macrophages in vitro. Infect. Immun. 66 (1998) 4080-4086
37. Mota M.M., Brown K.N., Do Rosario V.E., Holder A.A., and Jarra W. Antibody recognition of rodent malaria parasite antigens exposed at the infected erythrocyte surface: specificity of immunity generated in hyperimmune mice. Infect. Immun. 69 (2001) 2535-2541
38. 19 across distantly related Plasmodium species. Nat. Med. 6 (2000) 91-95
39. Plebanski M., Proudfoot O., Pouniotis D., Coppel R.L., Apostolopoulos V., and Flannery G. Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations. J. Clin. Invest. 110 (2002) 295-301
40. Rainczuk A., Scorza T., Smooker P.M., and Spithill T.W. Induction of specific T-cell responses, opsonizing antibodies, and protection against Plasmodium chabaudi adami infection in mice vaccinated with genomic expression libraries expressed in targeted and secretory DNA vectors. Infect. Immun. 71 (2003) 4506-4515
41. Rainczuk A., Smooker P.M., Kedzierski L., Black C.G., Coppel R.L., and Spithill T.W. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol. Vaccine 21 (2003) 3030-3042
42. Rainczuk A., Scorza T., Spithill T.W., and Smooker P.M. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria. Infect. Immun. 72 (2004) 5565-5573
43. Renia L., Ling I.T., Marussig M., Miltgen F., Holder A.A., and Mazier D. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect. Immun. 65 (1997) 4419-4423
44. Rotman H.L., Daly T.M., and Long C.A. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp. Parasitol. 91 (1999) 78-85
45. Saul A., Lord R., Jones G.L., and Spencer L. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2. J. Immunol. 148 (1992) 208-211
46. Sauzet J.P., Perlaza B.L., Brahimi K., Daubersies P., and Druilhe P. DNA immunization by Plasmodium falciparum liver-stage antigen 3 induces protection against Plasmodium yoelii sporozoite challenge. Infect. Immun. 69 (2001) 1202-1206
47. Scorza T., Grubb K., Smooker P.M., Rainczuk A., Proll D., and Spithill T.W. Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine. Infect. Immun. 73 (2005) 2974-2985
48. Shi Y.P., Udhayakuma V., Oloo A.J., Nahlen B.L., and Lal A.A. Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites. Am. J. Trop. Med. Hyg. 60 (1999) 135-141
49. Shi Y.P., Hasnain S.E., Sacci J.B., Holloway B.P., Fujioka H., Kumar N., Wohlhueter R., Hoffman S.L., Collins W.E., and Lal A.A. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc. Natl. Acad. Sci. USA 96 (1999) 1615-1620
50. Shi Y.P., Nahlen B.L., Kariuki S., Urdahl K.B., McElroy P.D., Roberts J.M., and Lal A.A. Fcgamma receptor IIa (CD32) polymorphism is associated with protection of infants against high-density Plasmodium falciparum infection. VII. Asembo Bay Cohort Project. J. Infect. Dis. 184 (2001) 107-111
51. Smooker P.M., Setiady Y.Y., Rainczuk A., and Spithill T.W. Expression library immunization protects mice against a challenge with virulent rodent malaria. Vaccine 18 (2000) 2533-2540
52. Smooker P.M., Rainczuk A., Kennedy N., and Spithill T.W. DNA vaccines and their application against parasites-promise, limitations and potential solutions. Biotechnol. Annu. Rev. 10 (2004) 189-236
53. Stevenson M.M., Su Z., Sam H., and Mohan K. Modulation of host responses to blood-stage malaria by interleukin-12: from therapy to adjuvant activity. Microbes Infect. 3 (2001) 49-59
54. Sulzer A.J., Deloron P., Cantella R.A., Collins W.E., and Nguyen-Dinh P. Antibodies to the ring-infected erythrocyte surface antigen of Plasmodium falciparum elicited by infection with Plasmodium malariae. Infect. Immun. 56 (1988) 729-733
55. Tan T.M., Goh K.L., Binh L.N., Ting R.C., and Kara U.A. Identification of a Plasmodium berghei antigen sharing common features with P. falciparum and P. chabaudi parasitophorous-vacuole membrane antigens. Parasitol Res. 82 (1996) 130-135
56. Taylor-Robinson A.W. Regulation of immunity to malaria: valuable lessons learned from murine models. Parasitol Today 11 (1995) 334-342
57. Triglia T., Healer J., Caruana S.R., Hodder A.N., Anders R.F., Crabb B.S., and Cowman A.F. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol. Microbiol. 38 (2000) 706-718
58. Wipasa J., Elliott S., Xu H., and Good M.F. Immunity to asexual blood-stage malaria and vaccine approaches. Immunol. Cell Biol. 80 (2002) 401-414
59. Wipasa J., Hirunpetcharat C., Mahakunkijcharoen Y., Xu H., Elliott S., and Good M.F. Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. J. Immunol. 169 (2002) 944-951
60. Xu L., Pei X., Berzins K., and Chaudhuri A. Plasmodium yoelii: Experimental evidences for the conserved epitopes between mouse and human malaria parasite, Plasmodium falciparum. Exp. Parasitol. 116 (2007) 214-224